Market capitalization | $0.00 |
Enterprise Value | $17.56m |
P/E (TTM) P/E ratio | 0.00 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 219.50 |
P/S ratio (TTM) P/S ratio | 0.00 |
P/B ratio (TTM) P/B ratio | 0.00 |
Revenue growth (TTM) Revenue growth | -98.65% |
Revenue (TTM) Revenue | $80.00k |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast Athersys, Inc.:
1 Analyst has issued a forecast Athersys, Inc.:
Sep '23 |
+/-
%
|
||
Revenue | 0.08 0.08 |
99%
99%
|
|
Gross Profit | -0.93 -0.93 |
118%
118%
|
|
EBITDA | -40 -40 |
51%
51%
|
EBIT (Operating Income) EBIT | -41 -41 |
51%
51%
|
Net Profit | -38 -38 |
54%
54%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.
Head office | United States |
CEO | Daniel Camardo |
Employees | 24 |
Founded | 1995 |
Website | www.athersys.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.